Smith Salley Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Smith Salley Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$207K	Buy	+417	New	+$185K	0.01%	267

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Smith Salley Wealth Management's VRTX Position: Q2 2026 in Review

Smith Salley Wealth Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 417 shares worth $207K. The stake represents 0.01% of the portfolio and ranks #267 among its holdings.

537 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Smith Salley Wealth Management held 417 shares of Vertex Pharmaceuticals worth $207K as of Q2 2026.
Vertex Pharmaceuticals was a new Smith Salley Wealth Management position in Q2 2026.
Vertex Pharmaceuticals made up 0.01% of Smith Salley Wealth Management's portfolio in Q2 2026, its #267 holding.
537 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Smith Salley Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.